@article{e5fc1da87dc14a96af26cb090211dd22,
title = "Tofacitinib in interstitial lung disease complicated with anti-MDA5 antibody-positive dermatomyositis: A literature review",
author = "Satoshi Takanashi and Yuko Kaneko and Tsutomu Takeuchi",
note = "Funding Information: S.T. reports no conflicts of interest relevant to this article. Y.K. has received grants or speaker fees from AbbVie, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Hisamitsu, Jansen, Kissei, Pfizer, Sanofi, Takeda, Tanabe-Mitsubishi, and UCB. T.T. has received research grants or speaking fees from Astellas Pharma Inc., Bristol–Myers K.K., Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo Co., Ltd, Takeda Pharmaceutical Co., Ltd, Teijin Pharma Ltd., AbbVie GK, Asahi Kasei Pharma Corp., Mitsubishi Tanabe Pharma, Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., AbbVie GK, Nippon Kayaku Co. Ltd, Janssen Pharmaceutical K.K., Taiho Pharmaceutical Co., Ltd., and Pfizer Japan Inc.",
year = "2021",
doi = "10.1080/14397595.2021.1906505",
language = "English",
journal = "Japanese Journal of Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
}